Breaking News From Pharma & Bio Ingredients
Quigley Pharma's QR-442 Compound Shows Positive Effect on Multiple Sclerosis Mouse Model
Posted on 2005-10-26 09:25:00
Quigley Pharma, a wholly-owned subsidiary of Quigley Corporation announced today the completion of an animal model study of its naturally derived compound QR-442. The murine experimental autoimmune encephalomyelitis (EAE) is an animal model for multiple sclerosis. The study included administering QR-442 to affected mice three times, at days, one, three and seven. The treated mice showed a delayed onset of disease and a significantly lower disease severity than those left untreated.
"We are encouraged by the study results," said Dr. Richard Rosenbloom, chief operating officer, Quigley Pharma. "A follow up study will begin immediately with more frequent dosing in an effort to see the drug's full potential."
According to the National Multiple Sclerosis Society, nearly 400,000 Americans have multiple sclerosis, and up to 2.5 million worldwide may be affected by the chronic disease of the brain and spinal cord.
The Quigley Corporation is the leading developer and marketer of diversified health products. The company's proven success in launching first-in-category health solutions supports the Pharma subsidiary in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes and rheumatoid arthritis with naturally derived compounds and botanicals.
Subscribe via RSS
